• 1
    Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update [in collaboration with the World Health Organization, GA(2)LEN and AllerGen]. Allergy 2008;63(Suppl. 86):8160.
  • 2
    Linneberg A, Henrik Nielsen N, Frolund L, Madsen F, Dirksen A, Jorgensen T. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study. Allergy 2002;57:10481052.
  • 3
    Corren J. Allergic rhinitis and asthma: how important is the link? J Allergy Clin Immunol 1997;99:S781S786.
  • 4
    Braunstahl GJ, Kleinjan A, Overbeek SE, Prins JB, Hoogsteden HC, Fokkens WJ. Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med 2000;161:20512057.
  • 5
    Braunstahl GJ, Overbeek SE, Fokkens WJ, Kleinjan A, McEuen AR, Walls AF et al. Segmental bronchoprovocation in allergic rhinitis patients affects mast cell and basophil numbers in nasal and bronchial mucosa. Am J Respir Crit Care Med 2001;164:858865.
  • 6
    Price D, Zhang Q, Kocevar VS, Yin DD, Thomas M. Effect of a concomitant diagnosis of allergic rhinitis on asthma-related health care use by adults. Clin Exp Allergy 2005;35:282287.
  • 7
    Corren J, Manning BE, Thompson SF, Hennessy S, Strom BL. Rhinitis therapy and the prevention of hospital care for asthma: a case–control study. J Allergy Clin Immunol 2004;113:415419.
  • 8
    Leynaert B, Neukirch C, Liard R, Bousquet J, Neukirch F. Quality of life in allergic rhinitis and asthma. A population-based study of young adults. Am J Respir Crit Care Med 2000;162:13911396.
  • 9
    Crystal-Peters J, Neslusan C, Crown WH, Torres A. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol 2002;109:5762.
  • 10
    Corren J, Adinoff AD, Buchmeier AD, Irvin CG. Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma. J Allergy Clin Immunol 1992;90:250256.
  • 11
    Adams RJ, Fuhlbrigge AL, Finkelstein JA, Weiss ST. Intranasal steroids and the risk of emergency department visits for asthma. J Allergy Clin Immunol 2002;109:636642.
  • 12
    Foresi A, Pelucchi A, Gherson G, Mastropasqua B, Chiapparino A, Testi R. Once daily intranasal fluticasone propionate (200 μg) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. J Allergy Clin Immunol 1996;98:274282.
  • 13
    The Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2008. Available from: 2008.
  • 14
    American Thoracic Society (ATS). ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005;171:912930.
  • 15
    Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000;161:309329.
  • 16
    Jokic R, Davis EE, Cockcroft DW. Methacholine PC20 extrapolation. Chest 1998;114:17961797.
  • 17
    Lipworth BJ, Seckl JR. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax 1997;52:476482.
  • 18
    Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of the mini asthma quality of life questionnaire. Eur Respir J 1999;14:3238.
  • 19
    Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Development and validation of the mini rhinoconjunctivitis quality of life questionnaire. Clin Exp Allergy 2000;30:132140.
  • 20
    Dempsey OJ, Fowler SJ, Wilson A, Kennedy G, Lipworth BJ. Effects of adding either a leukotriene receptor antagonist or low-dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma. Chest 2002;122:151159.
  • 21
    Inman MD, Hamilton AL, Kerstjens HA, Watson RM, O’Byrne PM. The utility of methacholine airway responsiveness measurements in evaluating anti-asthma drugs. J Allergy Clin Immunol 1998;101:342348.
  • 22
    Chinn S, Schouten JP. Reproducibility of nonspecific bronchial challenge in adults: implications for design, analysis and interpretation of clinical and epidemiological studies. Thorax 2005;60:395400.
  • 23
    Dahl R, Nielsen LP, Kips J, Foresi A, Cauwenberge P, Tudoric N et al. Intranasal and inhaled fluticasone propionate for pollen-induced rhinitis and asthma. Allergy 2005;60:87581.
  • 24
    Nathan RA, Yancey SW, Waitkus-Edwards K, Prillaman BA, Stauffer JL, Philpot E et al. Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. Chest 2005;128:19101920.
  • 25
    Van Den Berge M, Kerstjens HA, De Reus DM, Koeter GH, Kauffman HF, Postma DS. Provocation with adenosine 5′-monophosphate, but not methacholine, induces sputum eosinophilia. Clin Exp Allergy 2004;34:7176.
  • 26
    Sovijarvi AR, Haahtela T, Ekroos HJ, Lindqvist A, Saarinen A, Poussa T et al. Sustained reduction in bronchial hyperresponsiveness with inhaled fluticasone propionate within 3 days in mild asthma: time course after onset and cessation of treatment. Thorax 2003;58:500504.